AI Articles and Analysis about model development

Driven Approaches 
to Infrastructure

Driving Patient Experiences Through Data Science-Driven Approaches to Infrastructure – with Xiong Liu of Novartis

Explainable AI models are essential in pharmaceutical R&D because they provide transparency and understanding of how AI-driven predictions are made. In drug discovery and development, stakeholders, including researchers, regulatory bodies, and healthcare professionals, need to trust and understand AI models' outputs to make informed decisions. Without explainability, AI models can be seen as "black boxes," leading to skepticism and reluctance to adopt these technologies in critical decision-making processes. 

Banner template-4-min

Artificial Intelligence at KeyBank

KeyBank is a financial services institution with a rich history dating back to 1825 and headquartered in Cleveland, Ohio. With 17,000 employees, operations across 15 states, and assets totaling $187 billion, KeyBank's commitment to innovation is evident in its strategic application of AI technologies to enhance both workforce management and customer service. 

AI at Nationwide

Artificial Intelligence at Nationwide Insurance- Two Use Cases

Nationwide Mutual Insurance Company, commonly known as Nationwide, is a primary US insurance and financial services company headquartered in Columbus, Ohio.

Artificial Intelligence at AstraZeneca-1-min

Artificial Intelligence at AstraZeneca

AstraZeneca is a global biopharmaceutical company that researches, develops, manufactures, and markets prescription drugs and vaccines. Its key therapeutic areas include oncology, cardiovascular, renal, metabolism, respiratory, and immunology. In 2022, the company reported revenue of $42.67 billion and a profit of $4.08 billion. The company has a significant global presence, employing around 89,900 people across more than 60 countries as of 2023.

Leveled Approaches to AI for Asset Management Challenges-1-min

Leveled Approaches to AI for Asset Management Challenges – with Aman Thind of State Street

The asset management industry is going through several challenges, like the prolonged low-interest rate environment, dwindling margins, increased cost pressures, and squeezed profitability. Meanwhile, exponential growth in data volumes has overwhelmed legacy data management systems and analytical tools, making it tiring to process and extract valuable insights from the deluge of information. 

Artificial Intelligence at Electric Boat-min

Artificial Intelligence at General Dynamics Electric Boat

General Dynamics Electric Boat, a subsidiary of the General Dynamics Corporation founded in 1899, has set high standards in designing, building, and supporting submarines for the U.S. Navy. Its primary operations include a shipyard in Groton, CT, an automated hull-fabrication facility in Quonset Point, RI, and an engineering building in New London, CT. With over 14,000 employees, Electric Boat maintains a robust workforce dedicated to its mission of "designing, constructing, and providing life cycle support to the world's finest submarines."

The Market and Tech Forces Shaping the Future of Software Development-1

The Market and Tech Forces Shaping the Future of Software Development – with Tsavo Knott of Pieces

This article is sponsored by Pieces and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Overcoming Cultural and Technological Hurdles for AI Integration in Life Sciences-1-min

Overcoming Cultural and Technological Hurdles for AI Integration in Life Sciences – with Daniel Ferrante of Deloitte

Far beyond surface-level 'chatbot' software, and other customer-facing support systems, the same generative AI (GenAI) capabilities having direct impacts across language workflows in front-office tasks in financial and legal services is also having a direct impact on how research teams in the life sciences space are targeting solutions for rare diseases and novel treatments.